Antineoplastic Agents: Immunotherapeutic Agents
IPERJ1 “Perjeta injection” 30 mg/ml; 420 mg /vial
適應症：1.1 轉移性乳癌 PERJETA與trastuzumab及docetaxel併用於治療轉移後未曾以抗HER2 或化學療法治療之HER2陽性轉移性乳癌病患。1.2 乳癌的術前輔助療法 PERJETA與trastuzumab和docetaxel合併使用適用於HER2陽性、局部廣泛、發炎性或腫瘤大於2 cm或淋巴結陽性之早期乳癌， 作為完整治療處方之一部分。使用限制：尚未確立Perjeta用於包含doxorubicin療法的安全性。尚未確立對早期乳癌給予超過6個PERJETA療程的安全性。
Usual dose:
Adult:
Initial, 840 mg IV over 60 minutes; maintenance, 420 mg IV over 30 to 60 minutes every 3 weeks for 3 to 6 cycles.
Dose adjustment:
Renal impairment, mild to moderate (CrCl 30 to 90 mL/min): no dose adjustments needed. No data to CrCl < 30 mL/min.
Precaution:
Left ventricular ejection fraction decreases,and cardiac failure have been reported; monitoring recommended.
Infusion and hypersensitivity reactions, including anaphylaxis, have been reported; monitoring recommended.
Adverse effect:
Common:alopecia, rash, decrease in appetite, diarrhea, inflammatory disease of mucous membrane, nausea, vomiting, anemia, neutropenia, asthenia, headache, peripheral neuropathy, fatigue.
Serious:congestive heart failure, left ventricular cardiac dysfunction, anemia, febrile neutropenia, leukopenia, neutropenia, thrombocytopenia, anaphylaxis.